182 related articles for article (PubMed ID: 21841501)
1. Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.
Azzoli CG; Patel JD; Krug LM; Miller V; James L; Kris MG; Ginsberg M; Subzwari S; Tyson L; Dunne M; May J; Huntington M; Saunders M; Sirotnak FM
J Thorac Oncol; 2011 Nov; 6(11):1915-22. PubMed ID: 21841501
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer.
Ho AL; Lipson BL; Sherman EJ; Xiao H; Fury MG; Apollo A; Seetharamu N; Sima CS; Haque S; Lyo JK; Sales R; Cox L; Pfister DG
Invest New Drugs; 2014 Jun; 32(3):549-54. PubMed ID: 24566705
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.
Kelly K; Azzoli CG; Zatloukal P; Albert I; Jiang PY; Bodkin D; Pereira JR; Juhász E; Iannotti NO; Weems G; Koutsoukos T; Patel JD
J Thorac Oncol; 2012 Jun; 7(6):1041-8. PubMed ID: 22534814
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
Grem JL; Kos ME; Evande RE; Meza JL; Schwarz JK
Cancer; 2015 Nov; 121(21):3862-8. PubMed ID: 26242208
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
Azzoli CG; Krug LM; Gomez J; Miller VA; Kris MG; Ginsberg MS; Henry R; Jones J; Tyson L; Dunne M; Pizzo B; Farmer A; Venkatraman E; Steffen R; Sirotnak FM
Clin Cancer Res; 2007 May; 13(9):2692-8. PubMed ID: 17473201
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
[TBL] [Abstract][Full Text] [Related]
7. 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.
Krug LM; Azzoli CG; Kris MG; Miller VA; Khokhar NZ; Tong W; Ginsberg MS; Venkatraman E; Tyson L; Pizzo B; Baez V; Ng KK; Sirotnak FM
Clin Cancer Res; 2003 Jun; 9(6):2072-8. PubMed ID: 12796370
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.
Maruyama D; Nagai H; Maeda Y; Nakane T; Shimoyama T; Nakazato T; Sakai R; Ishikawa T; Izutsu K; Ueda R; Tobinai K
Cancer Sci; 2017 Oct; 108(10):2061-2068. PubMed ID: 28771889
[TBL] [Abstract][Full Text] [Related]
9. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
Hui J; Przespo E; Elefante A
J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.
Socinski MA; Raju RN; Neubauer M; Smith DA; Richards DA; Savin M; Ruxer RL; Reynolds CH; Zhan F; Bromund JL; Chen R; Obasaju C
J Thorac Oncol; 2008 Nov; 3(11):1308-16. PubMed ID: 18978567
[TBL] [Abstract][Full Text] [Related]
11. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies.
Molina JR
IDrugs; 2008 Jul; 11(7):508-21. PubMed ID: 18600598
[TBL] [Abstract][Full Text] [Related]
12. Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.
Parker T; Barbarotta L; Foss F
Future Oncol; 2013 Jan; 9(1):21-9. PubMed ID: 23252560
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
[TBL] [Abstract][Full Text] [Related]
14. Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
Chiappori A; Bepler G; Barlesi F; Soria JC; Reck M; Bearz A; Barata F; Scagliotti G; Park K; Wagle A; Liepa AM; Zhao YD; Chouaki N; Iscoe N; von Pawel J
J Thorac Oncol; 2010 Mar; 5(3):369-75. PubMed ID: 20090562
[TBL] [Abstract][Full Text] [Related]
15. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
Foss F; Horwitz SM; Coiffier B; Bartlett N; Popplewell L; Pro B; Pinter-Brown LC; Shustov A; Furman RR; Haioun C; Koutsoukos T; O'Connor OA
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):238-43. PubMed ID: 22542448
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemonaive patients with advanced non-small cell lung cancer.
Tournoux-Facon C; Robinet G; Pinel MC; Ferre P; Tourani JM
Am J Clin Oncol; 2012 Aug; 35(4):378-85. PubMed ID: 22814308
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
Foss FM
Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1141-52. PubMed ID: 21726160
[TBL] [Abstract][Full Text] [Related]
19. Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.
Shimanovsky A; Dasanu CA
Expert Opin Pharmacother; 2013 Mar; 14(4):515-23. PubMed ID: 23409799
[TBL] [Abstract][Full Text] [Related]
20. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Talpur R; Thompson A; Gangar P; Duvic M
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):297-304. PubMed ID: 24589156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
